Candel updates mid-stage data for lead drug (CADL:NASDAQ)

Candel Therapeutics (CADL) traded higher on Tuesday after the immunotherapy developer announced encouraging additional results from an ongoing mid-stage trial for its lead candidate, CAN-2409. Following an additional 12-month follow-up in its ongoing Phase 2a trial for the immunotherapy also ...